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Genome-wide identification 
of microRNA-related variants 
associated with risk of Alzheimer’s 
disease
Mohsen Ghanbari1,2, M. Arfan Ikram1,3,4, Hans W. J. de Looper5, Albert Hofman1,6, 
Stefan J. Erkeland7, Oscar H. Franco1 & Abbas Dehghan1
MicroRNAs (miRNAs) serve as key post-transcriptional regulators of gene expression. Genetic variation 
in miRNAs and miRNA-binding sites may affect miRNA function and contribute to disease risk. Here, 
we investigated the extent to which variants within miRNA-related sequences could constitute a part 
of the functional variants involved in developing Alzheimer’s disease (AD), using the largest available 
genome-wide association study of AD. First, among 237 variants in miRNAs, we found rs2291418 in 
the miR-1229 precursor to be significantly associated with AD (p-value = 6.8 × 10−5, OR = 1.2). Our 
in-silico analysis and in-vitro miRNA expression experiments demonstrated that the variant’s mutant 
allele enhances the production of miR-1229-3p. Next, we found miR-1229-3p target genes that are 
associated with AD and might mediate the miRNA function. We demonstrated that miR-1229-3p 
directly controls the expression of its top AD-associated target gene (SORL1) using luciferase reporter 
assays. Additionally, we showed that miR-1229-3p and SORL1 are both expressed in the human brain. 
Second, among 42,855 variants in miRNA-binding sites, we identified 10 variants (in the 3′ UTR of 9 
genes) that are significantly associated with AD, including rs6857 that increases the miR-320e-mediated 
regulation of PVRL2. Collectively, this study shows that miRNA-related variants are associated with AD 
and suggests miRNA-dependent regulation of several AD genes.
Alzheimer’s disease (AD) is the most common form of age-related neurodegenerative diseases worldwide mani-
fested by the progressive loss of memory and cognitive decline1. A number of cellular and molecular mechanisms 
lead to AD occurrence2–4. Over the past few decades, enormous efforts have been made to discover risk factors 
that play a role in development of AD and new biomarkers that help in early diagnosis of AD5,6. Recently, microR-
NAs (miRNAs), a class of small non-coding RNAs with 20–24 nucleotides (nt) long, have gained widespread 
attention as important modulators of different biological processes. They have been shown to be involved in 
biological and pathological processes in the brain7–9. In addition, a number of dysregulated miRNAs have been 
reported to be associated with AD and are suggested as potential diagnostic biomarkers for AD10–12. MiRNAs 
repress translation or decrease the stability of target messenger RNAs (mRNAs), by binding of the nucleotides 
2–8 from their 5′ end (known as the seed region) to complementary sequences in the 3′ UTR regions of target 
mRNAs13. MiRNAs are predicted to regulate the translation of up to 60% of all protein coding genes, indicating 
the involvement of miRNAs in most cellular processes14. Genetic variants in miRNA-encoding sequences can 
affect miRNA biogenesis and function15,16. Furthermore, variants that are located in the seed-matching regions 
of target genes may interfere with the interaction between miRNAs and their target genes, resulting in an altered 
expression level of the target transcript17,18. More recently, we and others have been able to show a number of 
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variants in genomic sequences encoding miRNAs or in the 3′ UTRs of miRNA target genes that contribute to 
phenotypic variations and disease risk18–22. However, the association of such variants with the risk of AD has not 
yet been systematically investigated.
In the present study, we hypothesized that miRNA-related variants could constitute a part of the functional 
genomic variants influencing the risk of AD. To test this hypothesis, we investigated the association of all genetic 
variants located in miRNA genes as well as miRNA-binding sites in the 3′ UTR of their target genes with risk of 
AD using data from the largest available GWAS on late-onset AD23. We subsequently integrated our results with 
publicly available biological databases (such as miRNA and gene expression profiles) and performed experimen-
tal studies to provide evidence for the function of the identified variants in AD.
Results
A flow chart of our approach to detect genetic variants within miRNAs and miRNA-binding sites that are associ-
ated with AD is shown in Fig. 1.
Association of genetic variants in miRNAs with AD. A polymorphism in miR-1229 was associated 
with AD. Out of 237 variants located in 206 miRNAs, we found rs2291418 (Chr5:179225324, A > G), a 
low-frequency variant (MAF = 0.02) in the pre-miR-1229 sequence, to be significantly associated with the risk 
of AD (p-value = 6.8 × 10−5 and OR = 1.2). Supplementary Fig. S1 shows the association of rs2291418 and other 
variants within the related locus with AD. The associations of all miRNA-variants that are nominally associated 
(at p-value < 0.05) with the risk of AD are shown in Supplementary Table S1.
The impact of rs2291418 on miR-1229 structure and expression. We generated the pre-miR-1229 hairpin struc-
tures containing the rs2291418 wild-type (G) and mutant (A) allele using the Vienna RNAfold algorithm24. We 
observed a − 4.2 kcal/mol difference in the minimum free energy of the thermodynamic ensemble of the predicted 
structure of pre-miR-1229 mutant compared to wild type (Fig. 2). This analysis indicated that the variant’s mutant 
allele may enhance the stability of the pre-miR-1229 hairpin, suggesting an improvement of the pre-miRNA 
Figure 1. Identification of variants in miRNAs and miRNA-binging sites associated with Alzheimer’s 
disease. This flow chart shows our approach to detect variants that are located in miRNA-related sequences and 
are associated with AD. GWAS, genome-wide association studies; LD, linkage disequilibrium.
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processing into the mature miR-1229. To experimentally show the impact of rs2291418 on the pre-miR-1229 
processing, we examined the expression levels of mature miR-1229 with the wild type and mutant pre-miRNA 
sequences. To this end, HEK293 cells were transfected with pMCSV vectors expressing transcripts with EGFP 
and wild type or mutant pre-miR-1229. Both the pre-miR-1229 wild type and pre-miR-1229 mutant transfected 
cells had equal levels of the EGFP-miRNA transcripts. However, the mature miR-1229-3p levels were significantly 
increased by 70% in cells transfected with pre-miR-1229 containing the mutant allele compared to the wild-type 
allele (p-value = 0.002) (Fig. 3), indicating that the variant improves the processing or stability of miR-1229.
Multiple miR-1229-3p target genes were associated with AD. We assessed which target genes of miR-1229-3p are 
implicated in pathways in nervous system or neurological disorders and may have a role in developing AD. To this 
end, we compiled a list of all predicted target genes of miR-1229-3p using the two most commonly used miRNA 
target prediction algorithms (TargetScan and miRanda) (n = 960). Both miRNA and its target genes should be 
expressed in the same tissue for any biological function to be exerted. Thus, we checked the expression of miR-
1229-3p in the brain. Our data showed that miR-1229-3p is abundantly expressed (average Ct-value: 28.8) in both 
white and gray matter of the human brain (Supplementary material, Table S2). In addition, miRNA expression 
databases (HMED and miRmine) show that miR-1229-3p is expressed at higher levels in the brain compared to 
other tissues, indicating an active regulatory role of miR-1229-3p on its target genes in the brain. Subsequently, 
we found that 750 miR-1229-3p target genes are expressed in the brain, using the Human Body Map 2.0 data.
Figure 2. Schematic view of the RNAfold predicted secondary structures of the pre-miR-1229 containing 
either the wild type or the mutant allele. (a) RNAfold predicted hairpin structure of the pre-miR-1229 with 
wild type allele and the minimum free energy (MFE) of the thermodynamic ensemble (Δ G). (b) RNAfold 
predicted hairpin structure of the pre-miR-1229 with the mutant allele. The pre-miRNA structure with lower 
MFE is expected to thermodynamically be more stable. The SNP position is shown by arrow.
Figure 3. The effect of rs2291418 on the expression level of miR-1229-3p. This figure illustrates a significant 
increase in the level of mature miR-1229-3p from the mutant allele A compared to the wild type allele G relative 
to GFP (p-value = 0.002).
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We then used the AD-GWAS data in a candidate gene approach to identify those target genes that are likely 
to be involved in developing AD23. We assessed the association of genetic variants in the 750 brain-expressed 
target genes of miR-1229-3p with AD. Supplementary Table S3 shows ten target genes of miR-1229-3p with the 
most significant association with AD. In addition, our pathway analysis using IPA demonstrated several target 
genes of miR-1229-3p to be involved in the network of Nervous System Development and Neurological disease 
(Supplementary material, Table S4).
miR-1229-3p-mediated regulation of SORL1. We selected SORL1, which is the most significant AD-associated 
target gene of miR-1229-3p, and examined whether the miRNA controls its expression level in vitro. We gen-
erated expression vector containing the pre-miR-1229-3p sequence and co-transfected the construct with 
Luciferase reporters containing the 3′ UTR (wild-type or mutant miR-1229-3p binding site) of SORL1. We found 
that over-expression of miR-1229-3p significantly decreases the Luciferase activity of the reporter containing the 
wild type SORL1 fragment, compared to the mutated SORL1 reporter (p-value = 0.003) (Fig. 4). In addition, this 
experiment showed a dose-dependent regulation of SORL1 by miR-1229-3p (Supplementary Fig. S2).The Human 
Body Map 2.0 data further show that SORL1 is abundantly expressed in the brain (Supplementary material, Table 
S3). These data strongly suggest for miR-1229-3p-mediated regulation of SORL1 in the human brain.
Association of genetic variants in miRNA-binding sites with AD. Ten miRNA binding site variants 
were associated with AD. We examined the association of 42,855 variants in putative miRNA-binding sites with 
AD that are illustrated in a Manhattan plot (Fig. 5). Of these, ten variants located in the 3′ UTR of 9 different 
genes passed the Bonferroni corrected significance threshold (p-value < 1.2 × 10−6). These variants would poten-
tially interfere with miRNA-mediated regulation of their host genes by disrupting, creating or modifying a num-
ber of miRNA-binding sites that are depicted in Supplementary Table S5. Out of 9 genes hosting the identified 
variants, the association of 7 genes with AD have been reported in the original GWAS (p-value < 5 × 10−8)23. 
In addition, we found two new susceptibility genes to be potentially associated with AD, including DMWD 
(p-value = 8.48 × 10−7) and HBEGF (p-value = 3.96 × 10−7). Regional plots showing association of the ten 
miRNA-binding site SNPs and their close by variants with AD are shown in Supplementary Fig. S2.
Functional annotation of the identified miRNA-binding site variants. We searched several databases and web 
tools to provide further insight into the functional role of ten AD-associated SNPs in miRNA-binding sites. 
Supplementary Table S6 shows a list of all web tools and databases that we used for our analyses. First, we exam-
ined the cis-expression quantitative trait loci (eQTLs) for 9 genes hosting the identified SNPs. We found that 
rs6857, rs2070736, rs2847655, rs10119 and rs610932 are correlated with differential expression levels of their 
host genes in blood (Table 1), showing that these SNPs alter expression levels of their host genes. In addition, 
the cis-regulatory effects of rs610932 and rs714948 on the expression of MS4A6A and PVR in cerebellum and 
temporal cortex have been reported25. Using the HaploReg web tool (v4), we found that 7 of the identified SNPs 
have no non-synonymous proxy SNPs in their loci, which suggest the identified SNPs are functional variants 
(Supplementary material, Table S7). The Human Body Map 2.0 RNA-seq data show that 8 out of the 9 host genes 
are expressed in the human brain. The miRNA expression databases further show that miR-214-3p, miR-212-5p, 
miR-204-3p, miR-362-3p, miR-450a and miR-320 are expressed in the brain. A summary of our findings regard-
ing on potential functionality of the ten identified variants in miRNA-binding sites are shown in Table 1 and 
Supplementary Table S7. These data suggest that the genes associated with AD containing variants in 3′ UTRs 
may be affected because of aberrant miRNA activities.
Figure 4. miR-1229-3p-mediated regulation of SORL1. This figure illustrates a significant decrease of the 
mean relative luciferase activity of wild type SORL1 reporter (TT), compared to the mutated SORL1 reporter 
(GG) in the presence of miR-1229-3p (p-value = 0.003).
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Discussion
Recent studies have shown the critical role of miRNAs in neuronal development and function19,26–28. In addition, 
a number of miRNAs have been reported to be implicated in the development of AD7–12. However, these studies 
were mainly focused on differentially expressed miRNAs and target genes using expression arrays in a small 
number of samples. There are also a few studies that have linked miRNAs with neurodegenerative disorders using 
genetic association in a candidate gene approach29,30. In this study, we performed a genome-wide investigation to 
identify genetic variants in miRNAs and in miRNA-binding sites that are associated with AD using data from the 
thus far largest GWAS on AD23.
We found that rs2291418 in the miR-1229 precursor, a miRNA which is abundantly expressed in the brain, is 
associated with the risk of AD. The pre-miR-1229 is precursor of two mature miRNAs (miR-1229-3p and miR-
1229-5p), however, the 3p miRNA has been shown to be the predominant product31. In silico analysis indicated 
that the mutant allele improves the stability of the hairpin structure of pre-miR-1229. Our miRNA expression 
experiments further showed that the mutant allele enhances the stability or processing of mature miR-1229-3p. 
It has been shown that variants located at the stem region of miRNA precursors could alter Drosha-mediated 
processing22,32,33. Although, many studies have shown that genetic variants within pre-miRNA sequences reduce 
the mature miRNA levels22,33,34, a few studies have reported such variants to enhance miRNA processing and 
expression33.
We revealed miR-1229-3p target genes that are associated with AD. An optimal approach would have been 
to check the co-expression of all potential target genes of miR-1229-3p in brain tissues and examine their cor-
relation with the miRNA expression to distill the potential mediators. However, collecting samples carrying 
the rare mutant allele (MAF = 0.03) of miR-1229-3p is challenging and was not possible for the investigators. 
Alternatively, we used GWAS data to identify the target genes that are more likely to be involved in the devel-
opment of AD. By this approach, we could highlight a number of miR-1229-3p target genes that are known for 
neurological-related pathways and diseases, including SORL1, MCFD2, COL25A1 and BMP235–37. This approach, 
however, may overlook certain target genes that mediate the miRNA function on AD. We experimentally verified 
that miR-1229-3p interacts with the predicted target site in the 3′ UTR of SORL1 which is the most significant 
AD-associated miR-1229-3p target and is abundantly expressed in the human brain. These data indicate that 
miR-1229-3p directly controls the expression of SORL1 in the brain. Several studies have reported decreased 
SORL1 expression to be mechanistically involved in causing AD37. It has been shown that SORL1 directs traf-
ficking of the amyloid precursor protein (APP) into recycling pathways and that when SORL1 is reduced, APP 
is sorted into amyloid beta peptide in AD35. Therefore, a higher expression level of miR-1229-3p in rs2291418 
mutant allele carriers may reduce SORL1 level and subsequently increase AD risk.
Furthermore, we identified ten variants in miRNA-binding sites that are associated with AD. Among them, 
rs6857 in PVRL2 is most significantly associated with AD38,39. The rs6857 mutant allele is predicted to create a 
target site for miR-320e in the 3′ UTR of PVRL2. Previously, we have experimentally shown that the expression 
of the mutant PVRL2 is regulated by miR-320e, resulting in a decreased level of the PVRL2 transcript18. In agree-
ment, the eQTL analysis showed a correlation between the rs6857 mutant allele and a lower expression level of 
PVRL2. Both PVRL2 and miR-320e are expressed in the brain40. These data suggest that rs6857 increases the risk 
of AD, at least in part, through down-regulation of PVRL2 by miR-320e.
We found that two SNPs in miRNA-binding sites of MS4A6A and MS4A2 are associated with AD susceptibil-
ity. SNP rs610932 within the 3′ UTR of MS4A6A is predicted to disrupt a binding site of miR-382-3p. MS4A6A 
Figure 5. Association of miRNA-binding site variants with Alzheimer’s disease. The Manhattan plot 
shows the association of 42,855 SNPs in miRNA-binding sites with AD. Dashed line indicates the significant 
study threshold which was set at 1.2 × 10−6. Genes hosting the variants significantly associated with AD are 
highlighted. The two newly identified genes for AD are depicted in red.
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is a well-known gene for susceptibility to AD25,41,42 and miR-382-3p is expressed in the brain. We observed that 
carriers of the minor allele containing rs610932 SNP, have a higher expression level of MS4A6A transcript in the 
blood eQTL data. The variant has been also shown to be associated with an altered expression level of MS4A6A in 
cerebellum and temporal cortex25. Therefore, an allele-specific regulation of MS4A6A by miR-328-3p may explain 
part of the observed association with AD. We also identified two SNPs in the 3′ UTR of PPP1R37 which can 
potentially disrupt binding sites of miR-219b-5p and miR-214-3p. PPP1R37 gene has previously been reported 
to be associated with AD and is expressed in the brain23,43. The both miRNAs, have been suggested to be impli-
cated in neuro-degenerative disorders including Parkinson’s and Huntington’s disease44. A disruption of miR-
214-3p and miR-219b-5p mediated regulations of PPP1R37 may be considered as a reason for the association of 
rs74846209 and rs1048699 with AD. Future experimental studies are needed to determine the function of these 
variants in AD.
We report DMWD and HBEGF as two new susceptibility genes for AD. First, the rs2070736 creates potential 
binding sites for miR-362-3p and miR-329-3p in the 3′ UTR of DMWD. These miRNAs and also DMWD are 
expressed in the brain45,46. The eQTL analysis further showed that the mutant allele is associated with lower 
expression level of the DMWD transcript, suggesting that rs2070736 change the expression levels of DMWD by 
affecting miRNA regulation. DMWD plays a role in developing mental symptoms in severe cases of myotonic 
dystrophy47. Interestingly, Alzheimer’s neurofibrillary changes in brain are reported to be present in myotonic 
dystrophy48. Together, the link between myotonic dystrophy and AD is notable and may indicate a potential 
role for DMWD in AD as well. Second, we found that rs7268 in the 3′ UTR of HBEGF is associated with AD 
and is expected to create a binding site for miR-205-5p, a brain-expressed miRNA. It has been reported that the 
membrane bound for HBEGF is constitutively expressed and present on the blood-brain barrier. HBEGF expres-
sion is also shown to be abundantly up-regulated in cerebral blood vessels in inflammatory situations such as 
AD, Parkinson’s disease, stroke, epilepsy and encephalitis49,50. Therefore, the aberrant miR-205-5p regulation of 
HBEGF could be a potential mechanism underlying the identified association.
In conclusion, in a genome-wide investigation, we identified a variant in miR-1229 and ten variants in 
miRNA-binding sites located in the gene 3′ UTRs that are associated with the risk of AD. Our in silico and 
in vitro analyses showed miR-1229-3p-mediated regulation of SORL1, which is a well-known gene involved in 
AD. Further experimental studies on the identified variants as well as miRNA profiling in AD patients are needed 
to determine the role of highlighted miRNAs and target genes in pathogenesis of AD. Finally, our study suggest 
altered miRNA-dependent regulation of genes due to variants in 3′ UTRs may explain part of the associations 
identified by GWAS.
Methods
Identification of genetic variants in miRNAs and miRNA-binding sites. We made a dataset of 
all genetic variants that are located in miRNA-related sequences using two online databases: miRNASNP and 
PolymiRTS51,52. The mature miRNAs of 20–24 nt in length are produced by processing of the precursor miRNAs 
(pre-miRNA) (60–80 nt)13. We thus investigated all variants that are located in human precursor and mature 
miRNA sequences. We retrieved a total of 2,420 variants in all miRNA-encoding sequences. We excluded variants 
with minor allele frequency (MAF) < 0.01. Of these, we included 237 single-nucleotide polymorphisms (SNPs) 
in 206 different miRNAs that were present in the recent GWAS of AD23. In addition, we retrieved almost 401,000 
variants in the 3′ UTR of all human miRNA target genes that are predicted to affect the match to the seed region 
of miRNAs. Of these, we included 42,855 SNPs with MAF > 0.01 and present in the GWAS of AD23.
Genome-wide association study on AD. To examine the association of variants in miRNA-related 
sequences with AD, we used the summary statistics data (stage 1) from the thus far largest GWAS on late-onset 
AD, including data from 17,008 AD cases and 37,154 controls on 7,055,881 SNPs, was reported by IGAP consor-
tium23. A description of the consortium data sets and participants are described elsewhere23. We adjusted p-value 
rs6857 rs2847655 rs610932 rs74846209 rs1048699 rs10119 rs714948 rs28399635 rs2070736 rs7268
GWAS
p-value 2.5 × 10−575 3.3 × 10−10 3.1 × 10−9 4.1 × 10−21 9.0 × 10−20 1.2 × 10−342 6.3 × 10−13 5.0 × 10−9 8.5 × 10−7 4.0 × 10−7
OR 3.2 1.1 0.9 2.3 1.2 1.3 1.1 0.9 1.1 1.1
Gene
Host gene PVRL2 MS4A2 MS4A6A PPP1R37 PPP1R37 TOMM40 PVR BCAM DMWD HBEGF
Brain Exp. 10.0 NA 6.2 11.0 11.0 9.7 5.7 3.0 11.5 9.2
miRBS
miRNA ID miR-320e miR-585-3p miR-382-3p miR-219b-5p miR-214-3p miR-516b-5p miR-1298-3p miR-450a-3p miR-362-3p miR-205-5p
Score change − 0.19 − 0.48 − 0.10 − 0.29 − 0.08 − 0.06 − 0.08 − 0.16 − 0.15 − 0.12
eQTL
Blood 9.5 × 10−5(− ) 6.5 × 10−22(− ) 2.1 × 10−35(+ ) − − + − − 2.4 × 10
−10 
(+ ) − 
Brain − − + − − − + − − − 
Proxy
Nr. proxies 0 94 72 18 18 0 1 0 18 8
Non-synon 0 0 1 1 1 0 0 0 0 0
Table 1.  A summary of supporting evidence for the potential functionality of the 10 identified miRNA-
binding site variants associated with Alzheimer’s disease. miRBS; miRNA binding site, OR; Odds ratio, 
Exp; Expression, Non-synon; Non-synonymous proxy SNP, NA; Not available. miRNAs in this table are highly 
conserved miRNAs related to the SNPs. Score change; Context score change using PolymiRTS database (v3.0).
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using Bonferroni correction for the number of tests and significant threshold was set at 2.1 × 10−4 (0.05/237) for 
SNPs in miRNAs and 1.2 × 10−6 (0.05/42,855) for SNPs in miRNA-binding sites.
Prediction of the variant effect on miRNA structure. When a miRNA-variant was associated with 
AD, we used the Vienna RNAfold algorithm (ViennaRNA package 2.0) to predict the effect of that variant on the 
secondary structure of the pre-miRNA (hairpin structure)24. The differences in minimum free energy (MFE) of 
the thermodynamic ensemble of pre-miRNA sequences containing the mutant versus the wild type alleles may 
affect the pre-miRNA that is processed to form mature miRNA.
Impact of variant on miRNA expression. We cloned the pre-miR-1229 sequence containing either the 
wild type or mutant allele behind the gene encoding green fluorescent protein (GFP) in the expression plasmid 
MSCV-BC (Murine Stem Cell Virus-Bar Coded)53, resulting in GFP-miRNA fusion transcripts. The inserts of all 
constructs were validated by Sanger sequencing. HEK293 cell transfection, total RNA isolation and quantitative 
PCRs were performed as previously described53. All primers are shown in Supplementary Table S8. The experi-
ment was performed in triplicate.
Association of miR-1229-3p target genes with AD. We compiled a list of all predicted target genes of 
the identified miRNA using two online databases, TargetScan v7.0 (http://www.targetscan.org)54 and miRanda 
(http://www.microrna. org/microrna)55. The miRNA target genes that are listed in both databases were used for 
our analyses. We then examined which of the miRNA putative targets are expressed in the human brain using the 
Human Body Map 2.0 RNA-seq data. Subsequently, we used the AD-GWAS data in a candidate gene approach to 
identify those target genes that are likely to be involved in AD. We retrieved the summary statistics for the associ-
ation of all genetic variants in the target genes with AD from the GWAS data. The significance threshold was set 
using the Bonferroni correction based on the number of studied SNPs. Additionally, we explored whether target 
genes of the identified miRNA may play a role in neurologic-related pathways. To do this, we used Ingenuity 
Pathway Analysis (IPA) (http://www.ingenuity.com/products/ipa/), a knowledge database generated from 
peer-reviewed scientific publications that enables the discovery of highly represented biological mechanisms, 
pathways or functions most relevant to the genes of interest from large, quantitative datasets. We uploaded all 
miRNA target genes and performed a core IPA analysis with default settings. We mapped the miRNA target genes 
to biological functions or canonical pathways to see whether they are enriched in neurologic-related networks.
Luciferase reporter assay. Primers were designed to amplify the 3′ UTR sequence of target gene included 
in the restriction enzyme sites XbaI for the forward primer and ApaI for the reverse. The SORL1 3′ UTR sequences 
(wild-type and mutated), containing the putative binding site of miR-1229-3p, were amplified and cloned into the 
pGL3 luciferase reporter vector downstream of the Luciferase open reading frame (Promega). The primers are 
shown in Supplementary Table S9. Similarly, pre-miR-1229 sequence was amplified using a forward primer contain-
ing a XhoI restriction site and a reverse primer containing a EcoRI restriction site. The amplified miRNA sequence 
was then cloned into the pMSCV-BC vector as previously described53. The inserts of all constructs were validated by 
Sanger sequencing. HEK293 cells were plated into 96-well plates and co-transfected with MSCV-miR-1229, pGL3 
vector containing the SORL1 3′ UTR and a plasmid expressing the Renilla transfection control. Luciferase activ-
ity was determined with the Dual-Glo Luciferase Assay System according to manufacturer’s protocol (Promega). 
Renilla luciferase activity was used for normalization. All experiments were performed in triplicate.
Expression of the identified miRNAs and target genes in relevant tissues. We examined the 
expression of miR-1229-3p in the human brain. The brain tissues (3 gray matter and 3 white matter) were 
obtained from the Netherlands Brain Bank (Amsterdam, The Netherlands). All samples were free of neurolog-
ical disease. For isolation of total RNA, five cryopreserved sections of 40 μ m were homogenized in 750 μ l Trizol 
LS reagent (Invitrogen, Carlsbad, CA, USA). Total RNA was isolated from 6 brain samples and. the concentra-
tion and purity of RNA samples were determined with a NanoDrop ND-1000 spectrophotometer (NanoDrop, 
Wilmington, DE). The expression level of miR-1229-3p was determined with TaqMan MicroRNA Assay accord-
ing to manufacturer’s protocol (Applied Biosystems, Foster City, CA, USA). RNU6B was used as an endogenous 
control. All experiments were performed in triplicate.
The Human Body Map 2.0 RNA-seq data (http://www.ensembl.info/blog/2011/05/24/human-body map-2-
0-data-from-illumina) was used to examine the expression of miRNA target genes across different tissues. To scan 
the expression of other miRNAs in the brain, we used HMED (http://bioinfo.life.hust.edu.cn/smallRNA/index.
php) and miRmine (http://guanlab.ccmb.med. umich.edu/mirmine/help.html) databases. Moreover, we used 
human miRNA expression data from four independent studies showing miRNAs that are differentially expressed 
(both up- and down-regulated) in different brain tissues and also AD patients40,46,56,57.
Functional characteristics of the identified miRNA-binding site variants. The list of variants in 
miRNA-binding sites associated with AD submitted to the SNAP web tool (http://www.broadinstitute.org/mpg/
snap/id) using R2 threshold > 0.8, limit distance 500 kb, and population panel CEU to retrieve their proxy SNPs 
in the 1000 Genomes project. We used the HaploReg (v4) web tool to predicts the effect of these SNPs on protein 
structure, gene regulation, and splicing. This analysis helps us to know whether there are other variants in high 
LD with the identified SNPs that may drive the observed association. We scanned the expression quantitative 
trait loci (cis-eQTL) data using GTEx (http://www.broadinstitute.org/gtex/) and HaploReg (4.1) that show the 
correlation of the variants with the expression of nearby genes in several tissues58,59. Other information, including 
miRNA sequences, host gene, miRNAs family and cluster amongst others, and miRNA conservation in different 
species was obtained from miRBase (release 20)60 and TargetScan (v7.0) databases.
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